EZH2 and prostate carcinoma: Next, we obtained mRNA from 18 matched normal and primary prostate cancer specimens (Table S2) and confirmed that MYC and EZH2 mRNA were indeed overexpressed in the prostate cancers (Wilcoxon signed ranked test, p<0.0002 for both) (Fig. 2B, S1A).